C4-carbonothioate-substituted tryptamine derivatives and methods of using
Disclosed are novel C 4 -carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
1. A chemical compound having chemical formula (I):
wherein R 4 is a carbonothioate moiety or a derivative thereof;
wherein R 3a and R 3b are each independently a hydrogen atom, an alkyl group, or an aryl group; and
wherein the carbonothioate moiety or derivative thereof has the chemical formula (III):
wherein R 4b is an optionally substituted alkyl group.
2. A chemical compound according to claim 1 , wherein R 4b is a C 1 -C 6 alkyl substituted with an aryl group.
3. A chemical compound according to claim 1 , wherein R 4b is C 1 -C 3 alkyl substituted with an aryl group.
4. A chemical compound according to claim 1 , wherein R 4b is a methylene (—CH 2 —) substituted with an aryl group.
5. A chemical compound according to claim 3 , wherein the aryl group is a phenyl group.
6. A chemical compound according to claim 4 , wherein the aryl group is a phenyl group.
7. A chemical compound according to claim 1 , wherein R 3a and R 3b are independently a C 1 -C 6 alkyl group.
8. A chemical compound according to claim 1 , wherein R 3a and R 3b are independently a C 1 -C 3 alkyl group.
9. A chemical compound according to claim 1 , wherein R 3a and R 3b are a methyl group.
10. A chemical compound according to claim 1 , wherein one of R 3a and R 3b is a C 1 -C 6 alkyl group, and the other of R 3a and R 3b is a hydrogen atom.
11. A chemical compound according to claim 1 , wherein R 4 is a carbonothioate moiety or derivative thereof, and wherein the compound is E(VI):
12. A pharmaceutical drug formulation comprising an effective amount of a chemical according to claim 1 , together with a pharmaceutically acceptable excipient, diluent, or carrier.
13. A pharmaceutical formulation according to claim 12 , wherein the pharmaceutical formulation is a pro-drug pharmaceutical formulation, wherein the compound having formula (I) is in vivo hydrolyzed to form a compound having chemical formula (VI):
wherein R 3a and R 3b are each independently a hydrogen atom, an alkyl group, or an aryl group.